TABLE 4.
Baseline characteristics of superResponders (no OCS use and no exacerbations during the first 6 months after benralizumab; ER0 = /OCS = 0) and non‐superResponders after 6 months of benralizumab treatment
| Non‐Super Responders (N = 45) | superResponders (N = 84) | p | |
|---|---|---|---|
| Mean age ± SD, year | 54.2 ± 13.6 | 53.0± 14.0 | NS |
| Female, n (%) | 28 (62.2) | 49 (70.2) | NS |
| Mean body weight ± SD, Kg | 73.6 ± 17.6 | 70.7 ± 15.1 | NS |
| Mean height ± SD, cm | 163.6 ± 10.0 | 164.3 ± 9.4 | NS |
| Mean body mass index ± SD, Kg/m2 | 27.1 ± 4.8 | 25.9 ± 5.6 | NS |
| Mean age at onset ± SD, year | 37.7 ± 13.7 | 34.1 ± 14.2 | NS |
| Mean disease length ± SD, year | 16.3 ± 10.1 | 19.0 ± 12.1 | NS |
| Atopy n (%) | 19 (42.2) | 42 (50.0) | NS |
| Smoking history | |||
| ‐ Current smoker, n (%) | 2(4.4) | 2(2.4) | NS |
| ‐ Ex smokers, n (%) | 13 (28.9) | 14 (16.7) | |
| ‐ Never smoker, n (%) | 30 (66.7) | 68 (81.0) | |
| Median Peripheral blood eosinophil count, cells/μl (IQR) | 680 (470, 920) | 747 (495, 1052) | NS |
| Median total serum IgE level, kU/L (IQR) | 114.0 (41–404) | 132.5 (66–472.5) | NS |
| ‐ Mean pre‐bronchodilator FEV1 ± SD, L | 1.7 ± 0.7 | 1.9 ± 0.8 | NS |
| ‐ Mean pre‐bronchodilatorFEV1 ± SD, %predicted | 60.8 ± 20.7 | 60.9 ± 20.6 | NS |
| ‐ Median FeNO 50, ppb (IQR) | 47.3 (23–59) | 49.0; (35–78) | NS |
| Exacerbation rate in year prior to benralizumab, n (mean ± SD) | 5.1 ± 4.2 | 5.0 ± 2.9 | NS |
| Drug use, number of patients | |||
| ‐ LAMA, n (%) | 36(80.0) | 58(69.0) | NS |
| ‐ OCS, n (%) | 33 (73.3) | 50 (59.5) | . 01 |
| ‐ Prednisone eq. dose in the previous 6 months, median(IQR) | 5 (0, 13) | 5 (0, 13) | NS |
| ‐ Leukotriene receptor antagonist, n (%) | 26 (57.8) | 39 (46.4) | . 005 |
| ‐ Azithromycin, n (%) | 13 (28.9) | 8 (9.5) | NS |
| ‐ Salbutamol daily puffs in the month before benralizumab (mean ± SD) | 2.7 ± 2.5 | 2.2 ± 2 | NS |
| ‐Immunotherapy, n (%) | 7 (15.6) | 24 (28.6) | NS |
| Comorbidities, number of patients | |||
| ‐ Nasal polyposis, n (%) | 18 (42.9) | 50 (64.9) | . 020 |
| ‐ Bronchiectasis, n (%) | 13 (28.9) | 16 (19.0) | NS |
| SNOT 22, mean ± SD | 49.4 ± 25 | 50.3 ± 16.9 | NS |
| ACT score at baseline, mean ± SD | 13.1 ± 4.5 | 13.8 ± 3.9 | NS |
| AQLQ score at baseline, mean ± SD | 3.5 ± 0.8 | 3.2 ± 1.3 | NS |
Abbreviations: ACT, Asthma control test; AQLQ, Asthma quality of life questionnaire; FeNO, Fractional exhaled nitric oxide; FEV1, Forced expiratory volume in 1 second; FVC, Forced vital capacity; IQR, Interquartile range; LAMA, Long‐acting muscarinic antagonist; OCS, Oral corticosteroids;SD, Standard deviation; SNOT‐22, Sino‐nasal outcome test; SPT, Skin prick test.